Zealand Pharma sells rusfertide royalty interests to Royalty Pharma for USD 100 million
RPRX•Royalty purchase agreement for rusfertide interests
Zealand Pharma sold its economic interests tied to rusfertide to Royalty Pharma for USD 100 million in a royalty purchase agreement.
The deal includes a 1% royalty on potential future global net sales, as well as regulatory milestones and commercial milestones.
USD 50 million is payable at closing, and the remaining USD 50 million is due on the first anniversary of closing.
Zealand retains a 0.25% royalty on annual net global sales above USD 1.5 billion; Royalty Pharma holds 0.75% above that level.
The transaction closed today. The FDA PDUFA goal date for rusfertide is set for Q3 2026.
